219 related articles for article (PubMed ID: 20445577)
1. BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.
Burke BA; Carroll M
Leukemia; 2010 Jun; 24(6):1105-12. PubMed ID: 20445577
[TBL] [Abstract][Full Text] [Related]
2. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients.
Marega M; Piazza RG; Pirola A; Redaelli S; Mogavero A; Iacobucci I; Meneghetti I; Parma M; Pogliani EM; Gambacorti-Passerini C
Leukemia; 2010 Aug; 24(8):1445-9. PubMed ID: 20520635
[TBL] [Abstract][Full Text] [Related]
3. BCR/ABL stimulates WRN to promote survival and genomic instability.
Slupianek A; Poplawski T; Jozwiakowski SK; Cramer K; Pytel D; Stoczynska E; Nowicki MO; Blasiak J; Skorski T
Cancer Res; 2011 Feb; 71(3):842-51. PubMed ID: 21123451
[TBL] [Abstract][Full Text] [Related]
4. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
Jin B; Wang C; Shen Y; Pan J
Cell Death Dis; 2018 Jan; 9(2):68. PubMed ID: 29358661
[TBL] [Abstract][Full Text] [Related]
5. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
van Rhee F; Hochhaus A; Lin F; Melo JV; Goldman JM; Cross NC
Blood; 1996 Jun; 87(12):5213-7. PubMed ID: 8652835
[TBL] [Abstract][Full Text] [Related]
6. [Research advance on molecular genetics of CML blast crisis].
Zhu HQ; Zhang S; Liu XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
[TBL] [Abstract][Full Text] [Related]
7. Structural organization of BCR-ABL gene in chronic phase and blast transformation in chronic myeloid leukemia patients.
Martinelli G; Zaccaria A; Farabegoli P; Buzzi M; Testoni N; Bragliani M; Panzica G; Tura S
Leuk Lymphoma; 1993; 11 Suppl 1():51-6. PubMed ID: 8251917
[TBL] [Abstract][Full Text] [Related]
8. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).
Desterke C; Voldoire M; Bonnet ML; Sorel N; Pagliaro S; Rahban H; Bennaceur-Griscelli A; Cayssials E; Chomel JC; Turhan AG
Exp Hematol; 2018 Aug; 64():71-83.e8. PubMed ID: 29733872
[TBL] [Abstract][Full Text] [Related]
9. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML.
Honda H; Ushijima T; Wakazono K; Oda H; Tanaka Y; Aizawa Si; Ishikawa T; Yazaki Y; Hirai H
Blood; 2000 Feb; 95(4):1144-50. PubMed ID: 10666183
[TBL] [Abstract][Full Text] [Related]
10. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.
Zhang JG; Lin F; Chase A; Goldman JM; Cross NC
Blood; 1996 Mar; 87(6):2588-93. PubMed ID: 8630427
[TBL] [Abstract][Full Text] [Related]
11. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
[TBL] [Abstract][Full Text] [Related]
13. Bcr/Abl interferes with the Fanconi anemia/BRCA pathway: implications in the chromosomal instability of chronic myeloid leukemia cells.
Valeri A; Alonso-Ferrero ME; Río P; Pujol MR; Casado JA; Pérez L; Jacome A; Agirre X; Calasanz MJ; Hanenberg H; Surrallés J; Prosper F; Albella B; Bueren JA
PLoS One; 2010 Dec; 5(12):e15525. PubMed ID: 21203397
[TBL] [Abstract][Full Text] [Related]
14. Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells.
Nakahara F; Kitaura J; Uchida T; Nishida C; Togami K; Inoue D; Matsukawa T; Kagiyama Y; Enomoto Y; Kawabata KC; Chen-Yi L; Komeno Y; Izawa K; Oki T; Nagae G; Harada Y; Harada H; Otsu M; Aburatani H; Heissig B; Hattori K; Kitamura T
Blood; 2014 Jun; 123(25):3932-42. PubMed ID: 24825862
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
[TBL] [Abstract][Full Text] [Related]
16. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia.
Zion M; Ben-Yehuda D; Avraham A; Cohen O; Wetzler M; Melloul D; Ben-Neriah Y
Proc Natl Acad Sci U S A; 1994 Oct; 91(22):10722-6. PubMed ID: 7938018
[TBL] [Abstract][Full Text] [Related]
17. BCR-ABL down-regulates the DNA repair protein DNA-PKcs.
Deutsch E; Dugray A; AbdulKarim B; Marangoni E; Maggiorella L; Vaganay S; M'Kacher R; Rasy SD; Eschwege F; Vainchenker W; Turhan AG; Bourhis J
Blood; 2001 Apr; 97(7):2084-90. PubMed ID: 11264175
[TBL] [Abstract][Full Text] [Related]
18. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
[TBL] [Abstract][Full Text] [Related]
19. Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Iqbal Z; Absar M; Mahmood A; Aleem A; Iqbal M; Jameel A; Akhtar T; Karim S; Rasool M; Mirza Z; Khalid M; Akram AM; Sabar MF; Khalid AM; Aljarrah K; Iqbal J; Khalid M; Shah IH; Alanazi N
Asian Pac J Cancer Prev; 2020 Dec; 21(12):3517-3526. PubMed ID: 33369447
[TBL] [Abstract][Full Text] [Related]
20. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.
Zhang H; Trachootham D; Lu W; Carew J; Giles FJ; Keating MJ; Arlinghaus RB; Huang P
Leukemia; 2008 Jun; 22(6):1191-9. PubMed ID: 18385754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
